The estimated Net Worth of Robert E Jr Farrell is at least $6.94 Milión dollars as of 8 July 2024. Mr. Farrell owns over 30,272 units of Morphic Inc stock worth over $785,379 and over the last 11 years he sold MORF stock worth over $6,152,428. In addition, he makes $0 as Senior Vice President - Finance a Chief Accounting Officer at Morphic Inc.
Robert has made over 21 trades of the Morphic Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 30,272 units of MORF stock worth $1,689,178 on 8 July 2024.
The largest trade he's ever made was selling 30,272 units of Morphic Inc stock on 8 July 2024 worth over $1,689,178. On average, Robert trades about 8,904 units every 54 days since 2014. As of 8 July 2024 he still owns at least 13,781 units of Morphic Inc stock.
You can see the complete history of Mr. Farrell stock trades at the bottom of the page.
Robert E. Farrell Jr. serves as Senior Vice President - Finance, Chief Accounting Officer of the Company. From March 2015 to June 2015, Mr. Farrell worked as an independent consultant. From April 2009 to March 2015, Mr. Farrell served as Vice President of Finance and Administration and Treasurer of Genocea Biosciences Inc. Previously, Mr. Farrell served in various senior level financial positions at Oscient Pharmaceuticals Corp., Magen Biosciences, Inc. and NeoGenesis Pharmaceuticals, Inc. Mr. Farrell received a B.S. in Accounting from Bentley University.
Robert Farrell is 54, he's been the Senior Vice President - Finance a Chief Accounting Officer of Morphic Inc since 2020. There are 5 older and 14 younger executives at Morphic Inc. The oldest executive at Morphic Holding Inc is Dr. Timothy A. Springer Ph.D., 73, who is the Founder, Independent Director & Member of Scientific Advisory Board.
Robert's mailing address filed with the SEC is C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM, MA, 02451.
Over the last 5 years, insiders at Morphic Inc have traded over $69,316,197 worth of Morphic Inc stock and bought 3,360,997 units worth $101,882,696 . The most active insiders traders include Plc Gsk, Holdings A/S Novo a Timothy A Springer. On average, Morphic Inc executives and independent directors trade stock every 13 days with the average trade being worth of $2,254,353. The most recent stock trade was executed by Bruce Rogers on 8 July 2024, trading 20,000 units of MORF stock currently worth $86,400.
oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
Morphic Inc executives and other stock owners filed with the SEC include: